NVAX Novavax

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu and a candidate vaccine for prevention of COVID-19. In June 2013, Novavax acquired the Matrix-M adjuvant platform with the purchase of Swedish company Isconova AB and renamed its new subsidiary Novavax AB.

Company profile

Stanley Erck
Fiscal year end
IRS number

NVAX stock data



28 Feb 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novavax earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 648.74M 648.74M 648.74M 648.74M 648.74M 648.74M
Cash burn (monthly) (positive/no burn) (positive/no burn) 60.95M 34.73M 42.86M 3.55M
Cash used (since last report) n/a n/a 210.63M 120.01M 148.1M 12.25M
Cash remaining n/a n/a 438.11M 528.73M 500.64M 636.49M
Runway (months of cash) n/a n/a 7.2 15.2 11.7 179.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Apr 21 Trizzino John Common Stock Sell Dispose S No Yes 178.03 191 34K 287
5 Apr 21 Trizzino John Common Stock Payment of exercise Dispose F No No 177.29 179 31.73K 478
5 Apr 21 Trizzino John Common Stock Sale back to company Dispose D No No 177.29 13 2.3K 657
5 Apr 21 Trizzino John Common Stock Option exercise Aquire M No No 177.29 383 67.9K 670
5 Apr 21 Trizzino John Common Stock Sell Dispose S No Yes 190.1 3,021 574.29K 287
5 Apr 21 Trizzino John Common Stock Option exercise Aquire M No Yes 5.95 2,083 12.39K 3,308
5 Apr 21 Trizzino John Common Stock Option exercise Aquire M No Yes 46 521 23.97K 1,225
5 Apr 21 Trizzino John Common Stock Option exercise Aquire M No Yes 27.6 417 11.51K 704
5 Apr 21 Trizzino John Stock Appreciation Right Common Stock Option exercise Dispose M No No 5.95 383 2.28K 11,501
5 Apr 21 Trizzino John Stock Option Common Stock Option exercise Dispose M No Yes 5.95 2,083 12.39K 62,501

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

52.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 347 302 +14.9%
Opened positions 98 120 -18.3%
Closed positions 53 25 +112.0%
Increased positions 114 90 +26.7%
Reduced positions 83 75 +10.7%
13F shares
Current Prev Q Change
Total value 4.71B 23.84B -80.3%
Total shares 38.89M 31.71M +22.6%
Total puts 4.89M 4.27M +14.7%
Total calls 3.35M 3.62M -7.5%
Total put/call ratio 1.5 1.2 +24.0%
Largest owners
Shares Value Change
Vanguard 5.6M $624.32M +3.1%
BLK Blackrock 5.13M $571.57M +19.3%
Ra Capital Management 3.79M $422.46M +216.1%
FMR 1.75M $195.21M +62.7%
STT State Street 1.73M $192.49M +1.0%
BEN Franklin Resources 1.28M $142.54M -43.1%
Susquehanna International 1.24M $138.27M +136.6%
Capital World Investors 1.19M $132.22M +2.5%
Perceptive Advisors 1.04M $116.31M +47.4%
Geode Capital Management 958.31K $106.86M +6.6%
Largest transactions
Shares Bought/sold Change
Ra Capital Management 3.79M +2.59M +216.1%
BEN Franklin Resources 1.28M -969.38K -43.1%
BLK Blackrock 5.13M +829.02K +19.3%
Susquehanna International 1.24M +715.86K +136.6%
FMR 1.75M +674.68K +62.7%
Norges Bank 558.69K +558.69K NEW
Point72 Asset Management 63.4K -534.02K -89.4%
Citadel Advisors 713.2K +389.54K +120.4%
Hillhouse Capital Advisors 0 -385.16K EXIT
Adage Capital Partners GP, L.L.C. 403.28K +378.28K +1513.1%

Financial report summary

  • We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.
  • Because we depend on third-parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.
Management Discussion
  • For our discussion of the year ended December 31, 2019, compared to the year ended December 31, 2018, please read Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations located in Annual Report on Form 10-K for the year ended December 31, 2019.
  • Revenue for 2020 was $475.6 million as compared to $18.7 million for 2019, an increase of $460.6 million. The significant increase in revenue in 2020 was a result of our development activities related to NVX-CoV2373 and was primarily comprised of revenue for services performed under the OWS Agreement and the CEPI Funding Agreement. Revenue for the year ended December 31, 2019 was primarily comprised of revenue for services performed under the BMGF Grant Agreement and recovery of costs on the close-out of our contract with HHS BARDA.
  • We expect revenue in 2021 to significantly increase due to our NVX-CoV2373 program, which we anticipate will continue to be funded by OWS and CEPI and/or other revenue sources. Further, we anticipate bringing our NVXCoV2373 vaccine candidate to market following global regulatory approvals which, if achieved, should significantly impact revenue (also see below under Liquidity and Capital Resources in this Management's Discussion and Analysis). In anticipation, we have entered into various APAs with government customers that are expected to result in the delivery of approximately 200 million doses of NVX-CoV2373 throughout 2021 and into the first half of 2022. We also entered into multiple supply and license agreements with strategic partners to supply NVX-CoV2373 in their specified territories under which we are entitled to receive royalty revenue from the sale of NVX-CoV2373 by such partners.
Content analysis
H.S. sophomore Avg
New words: accommodate, accrual, advice, African, AGC, Aid, allegedly, Alliance, allotted, alter, altogether, Alton, American, APA, APC, appraisal, arena, Asian, ATI, Australian, automated, automatic, Azar, back, ballot, bar, bark, begun, bench, Billingham, Bilt, Bilthoven, Biosafety, bioscience, bivalent, blinded, Bohumil, bold, bona, boost, boosting, bribery, Britain, Buyer, California, Canadian, cancer, Carolina, CBRN, CCPA, CDMO, cell, Centre, certified, certiorari, cholesterol, Circuit, client, CMO, CMS, coaching, coincide, commensurate, comment, Commissioner, Commonwealth, composed, concealing, concierge, configuration, Congressional, Consortium, constrain, constraint, consummated, convalescent, convenience, convenient, convicted, Council, countermeasure, COVAX, Covino, CPRA, Creation, creativity, CRO, crossover, culture, customary, Cut, cybersecurity, CZ, Czech, database, David, de, debarment, degradation, DEI, delegated, delete, demographic, devise, diagnose, disaster, discretion, distancing, District, DoD, drop, EAC, embezzling, encoding, endeavoring, Energy, England, entirety, environment, equitable, escape, EUA, evidencing, evolution, exact, expedient, expenditure, explicitly, explore, exploring, falsifying, FCA, FCPA, FDB, fide, fill, filling, folded, forefront, forgivable, forma, formulary, fortunate, frequency, frugiperda, FUJIFILM, fused, gave, Gavi, geolocation, goal, grandfathered, grantor, Great, Gregg, GSK, guarantor, halt, harbor, harmonized, Hatch, heading, heard, heavily, HITECH, illustrated, imaging, imbued, IMM, implicitly, inactivated, injection, injunction, injured, Inovio, input, inserted, inseverable, interdependent, interrelated, iPDP, Ireland, irregularity, irreversible, Johnson, joined, joining, jointly, Judge, judgment, knowledge, Korea, Korean, Koruna, Labour, landscape, LatinX, Learning, led, legitimate, lessee, lessor, leverage, leveraging, library, linked, LinkedIn, loan, lowest, LV, lymph, Majesty, managerial, Margaret, mask, Matter, McGlynn, meaningfully, mechanism, Medsafe, Member, Memorandum, memory, met, Mexico, MHRA, Minister, Ministry, misconduct, moderate, modification, Molina, month, Montreal, Mott, MOU, mutual, nanometer, nationwide, necessitate, necessity, negligence, network, networking, noncash, nonclinical, noncompliance, North, Northern, notify, Nuclear, numerically, nurse, nurture, NVX, occupy, offense, official, online, onset, onsite, opt, optimistic, oral, outbreak, outpatient, output, outsized, overcome, pace, paired, Park, partnership, paused, perception, phospholipid, physician, placement, platform, play, PMDA, polyfunctional, Polypeptide, Poonawalla, Portability, posted, power, Praha, precise, preclude, predetermined, predominant, preliminarily, PREP, prepay, principle, pro, problem, procured, procurement, proud, punishable, Queen, RA, Radiological, randomly, reaction, reactogenicity, reallocate, Rebate, recall, receptor, recoup, refund, relief, relocated, remanded, remeasure, remote, remotely, Removal, remove, renovation, reproduction, Republic, reschedule, revocation, role, royalty, sabotage, safer, saponin, screening, sera, Serial, seropositive, SIIPL, Similarly, Sinopharm, Sinovac, SK, slated, social, solidify, solving, South, speculation, Spodoptera, standalone, stay, stealing, stemming, stockpile, strict, subcontractor, subpopulation, Subscription, substantive, sued, SUKL, supplier, Supreme, Switzerland, Takeda, talent, Taskforce, Taxpayer, TCJA, teaching, team, technique, temperature, temporal, terrorism, TGA, therapy, thought, tiered, timeline, today, tracker, travel, treasury, trend, tuition, unblinded, unconstitutional, Undefinitized, uneven, unexpected, unfair, unfunded, unilaterally, unmanaged, unprecedented, unprofitable, unrecoverable, unrest, unsatisfied, unsuitable, unusual, urgent, vacation, variant, video, voluntary, war, Warp, water, Waxman, weather, welfare, whistleblower, willfully, Zealand
Removed: Ablynx, accumulation, activation, adjusted, allergic, amplitude, anniversary, arbitrary, awardee, bacteria, Bavarian, bid, Bipartisan, Carlo, carried, cellular, cheaper, climate, Clopper, comparability, confirmatory, conformation, correlation, CPLB, curb, cure, cytotoxic, Datamonitor, delist, delisted, delisting, device, difficulty, diluting, disposable, Dr, enactment, excellent, expiring, exploratory, feasible, Frech, GE, GEHC, generating, hampered, hemagglutination, hidden, immunological, immunologically, immunostimulatory, Immunovaccine, inhibition, innate, leasing, listing, Mab, maximizing, monoclonal, Monte, NIAID, nominal, Nordic, originally, participating, particle, pathogen, physical, poorly, prequalification, preservation, preterm, prioritize, projection, prolong, QUALITATIVE, qualitatively, recoverability, recurring, regulator, repeating, replication, retained, revised, risen, Rock, Sarah, season, seasoned, simulation, spouse, stimulate, structure, SUPPLEMENTARY, synthetic, transition, undiscounted, Vaxart, win, Wyeth